Phio Pharmaceuticals Corp. Files 8-K

TL;DR

Phio Pharma filed an 8-K on Jan 13, 2025, for a material agreement. Details TBD.

AI Summary

On January 13, 2025, Phio Pharmaceuticals Corp. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. The exact nature of the agreement and its financial implications are not detailed in this filing excerpt.

Why It Matters

This 8-K filing indicates a significant event for Phio Pharmaceuticals Corp., potentially involving a new agreement that could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks for the company, but the lack of specific details necessitates a medium risk assessment.

Key Players & Entities

• Phio Pharmaceuticals Corp. (company) — Registrant
• January 13, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Marlborough, Massachusetts (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — h registered: Common Stock, par value $0.0001 per share PHIO The Nasdaq Capital M
• $3.00 — "Common Stock"), at a purchase price of $3.00 per share. Pursuant to the Securities P
• $2.85 m — the Private Placement is approximately $2.85 million, after deducting fees and estimat
• $25,000 — Offering and the Private Placement and $25,000 for non-accountable expenses, and $15,9
• $15,950 — 5,000 for non-accountable expenses, and $15,950 for clearing fees. In addition, the Com
• $3 — arrants have an exercise price equal to $3.75, or 125% of the offering price per s

Filing Documents

• phio_8k.htm (8-K) — 40KB
• phio_ex0401.htm (EX-4.1) — 112KB
• phio_ex0402.htm (EX-4.2) — 113KB
• phio_ex0501.htm (EX-5.1) — 8KB
• phio_ex1001.htm (EX-10.1) — 258KB
• phio_ex9901.htm (EX-99.1) — 14KB
• image_003.jpg (GRAPHIC) — 2KB
• 0001683168-25-000347.txt ( ) — 844KB
• phio-20250113.xsd (EX-101.SCH) — 3KB
• phio-20250113_lab.xml (EX-101.LAB) — 33KB
• phio-20250113_pre.xml (EX-101.PRE) — 22KB
• phio_8k_htm.xml (XML) — 4KB

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities. The disclosures in Item 1.01 of this Form 8-K regarding the Series G Warrants, the Warrant Shares, the Placement Agent Warrants and the shares of Common Stock issuable thereunder are incorporated by reference into this Item 3.02.

01. Other Events

Item 8.01. Other Events. On January 14, 2025 , the Company issued a press release announcing the pricing of the Registered Direct Offering and the Private Placement. The full text of the press releases is attached hereto as Exhibit 99.1 and incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Number Description 4.1 Form of Series G Common Stock Warrant, dated January 14, 2025 . 4.2 Form of Placement Agent Warrant, dated January 14, 2025 . 5.1 Opinion of Hogan Lovells US LLP. 10.1 Form of Securities Purchase Agreement, dated January 13, 2025 , by and between the Company and each of the Purchasers signatory thereto. 23.1 Consent of Hogan Lovells US LLP (contained in Exhibit 5.1 ). 99.1 Press Release issued by the Company on January 14, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: January 14, 2025 By: /s/ Robert Bitterman Robert Bitterman President & Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR